Modulation of cd40 expression

作者: C. Frank Bennett , Susan M. Freier , Lex M. Cowsert

DOI:

关键词:

摘要: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration targeted to CD40 include hyperproliferative disorders, graft versus host (GVHD), rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), certain forms arthritis.

参考文章(312)
Ghosh K, Ghosh Mk, Cohen Js, Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for antisense application. Anti-cancer Drug Design. ,vol. 8, pp. 15- 32 ,(1993)
GEORG SCZAKIEL, MATTHIAS HOMANN, KAROLA RITTNER, Computer-Aided Search for Effective Antisense RNA Target Sequences of the Human Immunodeficiency Virus Type 1 Antisense research and development. ,vol. 3, pp. 45- 52 ,(1993) , 10.1089/ARD.1993.3.45
Kelly Sprankle, Muthiah Manoharan, Ole Buchardt, Michael Egholm, Peter Nielsen, Michael Griffith, John Kiely, Jesper Lohse, Soren Holst Sonnichsen, Peptide nucleic acid conjugates ,(1995)
John Goodchild, Paul C. Zamecnik, Inhibition of htlv-iii by exogenous oligonucleotides ,(1987)
A. David Adams, Richard B. Meyer, Charles Robert Petrie, Oligo(alpha-arabinofuranosyl nucleotides) and alpha-arabinofuranosyl precursors thereof ,(1991)